Security Snapshot

CONSTELLATION PHARMCETICLS I - COM (CNST) Institutional Ownership

CUSIP: 210373106

13F Institutional Holders and Ownership History from Q3 2018 to Q3 2021

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • CNST - CONSTELLATION PHARMCETICLS I - COM is tracked under CUSIP 210373106.
  • 13F reference-period holder data is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder data for the Q3 2026 reference period is not available.
  • Available periods remain in the history table; they do not substitute for the headline period.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

210373106

13F reference period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
13
Headline period
n/a
Rows shown
1-13 of 13
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2021 Q3 0 $0 -$1,391,207,870 0
2021 Q2 43,791,389 $1,480,142,299 -$157,353,282 $33.80 150
2021 Q1 51,737,664 $1,211,904,602 +$24,169,267 $23.39 128
2020 Q4 50,716,697 $1,460,667,424 -$6,348,118 $28.80 133
2020 Q3 49,301,088 $998,847,612 -$5,132,287 $20.26 117
2020 Q2 48,148,332 $1,445,213,343 +$211,319,211 $30.05 127
2020 Q1 38,875,805 $1,221,862,863 +$9,654,737 $31.43 96
2019 Q4 32,140,688 $1,514,142,962 +$871,757,330 $47.11 98
2019 Q3 19,980,278 $129,069,236 +$23,394,438 $6.46 47
2019 Q2 16,615,219 $204,018,150 +$88,786 $12.28 48
2019 Q1 16,610,078 $225,063,878 +$16,268,736 $13.55 44
2018 Q4 15,481,032 $61,896,317 -$1,259,160 $4.01 35
2018 Q3 10,935,163 $72,981,000 +$72,532,000 $6.73 33
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .